ВОЗМОЖНОСТЬ ПРИМЕНЕНИЯ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ У ПАЦИЕНТОВ С ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИЕЙ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПРИ НЕСТАНДАРТНЫХ СИТУАЦИЯХ

Πηγή: Высшая школа: научные исследования.

Θεματικοί όροι: ДГПЖ, хирургическое лечение, Доброкачественная гиперплазия предстательной железы, трансуретральная резекция предстательной железы, ТУР ПЖ

ASSESSMENT OF RISK FACTORS FOR DEVELOPMENT OF URETHRAL STRICTURES AND BLADDER NECK SCLEROSIS IN PATIENTS WHO HAVE UNDERWENT SURGERY FOR BENIGN PROSTATE HYPERPLASIA: ОЦЕНКА ВКЛАДА ФАКТОРОВ РИСКА В РАЗВИТИЕ СТРИКТУР УРЕТРЫ И СКЛЕРОЗА МОЧЕВОГО ПУЗЫРЯ У ПАЦИЕНТОВ, ПЕРЕНЕСШИХ ОПЕРАТИВНОЕ ВМЕШАТЕЛЬСТВО ПО ПОВОДУ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Συγγραφείς: Kairambayev, Ye.М., Sidekhmenov, V.A., Mailybayev, A.C., Bulegenov, T.А., Neimark, A.I., Akhmetova, A.K., Urazalina, Zh.M., Pivin, M.R., Pivina, L.M.

Πηγή: Наука и здравоохранение. :91-96

Θεματικοί όροι: 2. Zero hunger, benign prostatic hyperplasia, қуық мойын склерозы, склероз шейки мочевого пузыря, трансуретральды резекция, стриктура уретры, 6. Clean water, 3. Good health, қуықасты безінің қатерсіз гиперплазиясы, отношение шансов, уретральды стриктура, transurethral resection, odds ratio, доброкачественная гиперплазия простаты, urethral stricture, 10. No inequality, sclerosis of the bladder neck, трансуретральная резекция, ықтималдық қатынасы

Comparison of thulium and holmium lasers with conventional transurethral bladder resection for non-muscle invasive bladder cancer ; Сравнение тулиевого и гольмиевого лазеров с традиционной трансуретральной резекцией мочевого пузыря при немышечно-инвазивном раке мочевого пузыря

Συγγραφείς: S. V. Popov, R. G. Huseynov, E. V. Pomeshkin, O. N. Scriabin, K. V. Sivak, V. V. Perepelitsa, T. A. Lelyavina, E. A. Malyshev, С. В. Попов, Р. Г. Гусейнов, Е. В. Помешкин, О. Н. Скрябин, К. В. Сивак, В. В. Перепелица, Т. А. Лелявина, Е. А. Малышев

Πηγή: Urology Herald; Том 12, № 3 (2024); 70-78 ; Вестник урологии; Том 12, № 3 (2024); 70-78 ; 2308-6424 ; 10.21886/2308-6424-2024-12-3

Θεματικοί όροι: мочевой пузырь, transurethral resection of the bladder, laser resection, recurrence, bladder, трансуретральная резекция мочевого пузыря, лазерная резекция, рецидив

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/884/564; Гусниев М.А., Печникова В.В., Гущин М.Ю., Гусниев С.А., Гиоева З.В., Пшихачев А.М., Михалева Л.М. Анализ факторов риска рецидива немышечно-инвазивного рака мочевого пузыря после его комбинированного лечения. Медицинский вестник Северного Кавказа. 2022;17(3):264-268. DOI:10.14300/mnnc.2022.17064; Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodríguez Faba Ó, Briganti A, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021;39(10):642-663. DOI:10.1016/j.urolonc.2021.05.015; Иванов С.А., Заборский И.Н., Чайков В.С. Лечение немышечно-инвазивного рака мочевого пузыря высокого риска. Вестник урологии. 2017;5(2):42-49. DOI:10.21886/2308-6424-2017-5-2-42-49; Al Hussein Al Awamlh B, Chang SS. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Curr Oncol Rep. 2023;25(2):83-91. DOI:10.1007/s11912-022-01350-9; Бабаевская Д.И., Базаркин А.К., Тараткин М.С., Еникеев Д.В. Новейшие достижения в трансуретральной резекции стенки мочевого пузыря с опухолью. Вестник урологии. 2022;10(1):96-103. DOI:10.21886/2308-6424-2022-10-1-96-103; Ивахно К.Ю., Важенин А.В., Карнаух П.А., Мисюкевич Н.Д. Мировой опыт применение тулиевого лазера в лечении мышечно-неинвазивного рака мочевого пузыря. Вестник Совета молодых учёных и специалистов Челябинской области. 2018;2(1):111-112. eLIBRARY ID: 35010553; EDN: XOXQBV; Li C, Gao L, Zhang J, Yang X, Liu C. The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Lasers Med Sci. 2020;35(5):1025-1034. DOI:10.1007/s10103-020-02972-w; Chen J, Zhao Y, Wang S, Jin X, Sun P, Zhang L, Wang M. Green-light laser en bloc resection for primary non-muscle-invasive bladder tumor versus transurethral electroresection: A prospective, nonrandomized two-center trial with 36-month follow-up. Lasers Surg Med. 2016;48(9):859-865. DOI:10.1002/lsm.22565; Xu Y, Guan W, Chen W, Xie C, Ouyang Y, Wu Y, Liu C. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. Lasers Surg Med. 2015;47(4):306-311. DOI:10.1002/lsm.22342; Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, Fan ZL, Han P, Huang YR, Huang X, Li M, Li XD, Li YN, Li XH, Liang CZ, Liu JM, Ma HS, Qi J, Shi JQ, Wang J, Wang DL, Wang ZP, Wang YY, Wang YB, Wei Q, Xia HB, Xing JC, Yan SY, Zhang XP, Zheng GY, Xing NZ, He DL, Wang XH; Chinese Urological Doctor Association (CUDA), Urological Association of Chinese Research Hospital Association (CRHA-UA), Uro-Health Promotive Association of China International Exchange, Promotive Association for Medical, Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44. DOI:10.1186/s40779-022-00406-y; Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res. 2022;14:35-48. DOI:10.2147/CEOR.S341896; Liem EIML, Freund JE, Savci-Heijink CD, de la Rosette JJMCH, Kamphuis GM, Baard J, Liao JC, van Leeuwen TG, de Reijke TM, de Bruin DM. Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading. Eur Urol Focus. 2020;6(1):81-87. DOI:10.1016/j.euf.2018.07.012; Poletajew S, Krajewski W, Gajewska D, Sondka-Migdalska J, Borowik M, Buraczyński P, Dzięgała M, Łykowski M, Przudzik M, Tukiendorf A, Woźniak R, Bar K, Jabłonowski Z, Roslan M, Słojewski M, Zdrojowy R, Radziszewski P, Dziobek K. Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour - a prospective multicentre observational study. Arch Med Sci. 2019;16(4):863-870. DOI:10.5114/aoms.2019.88430; Kamadjou C, Kuitche J, Wadeu A, Mbassi A, Angwafo F. Transurethral Resection of Bladder Tumours: Results and Outcomes. Open Journal of Urology. 2022;12:342-356. DOI:10.4236/oju.2022.126033; Lonati C, Esperto F, Scarpa RM, Papalia R, Gómez Rivas J, Alvarez-Maestro M, Afferi L, Fankhauser CD, Mattei A, Colombo R, Montorsi F, Briganti A, Krajewski W, Carando R, Laukhtina E, Teo JY, Zamboni S, Simeone C, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YA U): Urothelial Carcinoma Working Group; European Association of Urology - European Society of Resident Urologists (EAU-ESRU). Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. Minerva Urol Nephrol. 2022;74(5):570-580. DOI:10.23736/S2724-6051.21.04436-0; Long G, Zhang Y, Sun G, Ouyang W, Liu Z, Li H. Safety and efficacy of thulium laser resection of bladder tumors versus transurethral resection of bladder tumors: a systematic review and meta-analysis. Lasers Med Sci. 2021;36(9):1807-1816. DOI:10.1007/s10103-021-03272-7; https://www.urovest.ru/jour/article/view/884

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/884
https://doi.org/10.21886/2308-6424-2024-12-3-70-78

Simultaneous treatment of anterior urethral stricture and benign prostatic hyperplasia: primary experience overview ; Симультанное лечение стриктуры передней уретры и доброкачественной гиперплазии предстательной железы: начальный опыт

Συγγραφείς: M. I. Katibov, A. B. Bogdanov, M. M. Alibekov, Z. M. Magomedov, O. B. Loran, М. И. Катибов, А. Б. Богданов, М. М. Алибеков, З. М. Магомедов, О. Б. Лоран

Πηγή: Urology Herald; Том 12, № 1 (2024); 27-35 ; Вестник урологии; Том 12, № 1 (2024); 27-35 ; 2308-6424 ; 10.21886/2308-6424-2024-12-1

Θεματικοί όροι: тулиевый лазер, benign prostatic hyperplasia, transurethral resection, laser enucleation, thulium laser, доброкачественная гиперплазия предстательной железы, трансуретральная резекция, лазерная энуклеация

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/827/531; Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403-415, v. DOI:10.1016/j.ucl.2009.07.003; Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79(5):1111-1116. DOI:10.1016/j.urology.2011.11.084; Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol. 2009;55(6):1345-1357. DOI:10.1016/j.eururo.2009.03.070; Patel A, Nunez R, Mmeje CO, Humphreys MR. Safety and feasibility of concomitant surgery during holmium laser enucleation of the prostate (HoLEP). World J Urol. 2014;32(6):1543-1549. DOI:10.1007/s00345-014-1254-0; Myers JB, McAninch JW. Perineal urethrostomy. BJU Int. 2011;107(5):856-865. DOI:10.1111/j.1464-410X.2011.10139.x; Bracka A. A versatile two-stage hypospadias repair. Br J Plast Surg. 1995;48(6):345-352. DOI:10.1016/s0007-1226(95)90023-3; Chong T, Li YQ, Wang ZM, Shi T, Zhang P. [Simultaneous treatment for benign prostate hyperplasia and its concomitant diseases]. Zhonghua Nan Ke Xue. 2006;12(6):534-536. (In Chinese) PMID: 16833196; Коган М.И., Митусов В.В., Красулин В.В., Шангичев А.В., Глухов В.П., Аметов Р.Э., Митусова Е.В. Внутренняя оптическая уретротомия при стриктурной болезни уретры усложняет последующую реконструктивную операцию. Урология. 2012;(3):27-30. eLIBRARY ID: 18065089; EDN: PFIHBD; Коган М.И. Комментарии к новым поправкам (2023) в рекомендации Американской урологической ассоциации по стриктурной болезни уретры. Вестник урологии. 2023;11(3):5-9. DOI:10.21886/2308-6424-2023-11-3-5-9; Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral Stricture Disease Guideline Amendment (2023). J Urol.2023;210(1):64-71. DOI:10.1097/JU.0000000000003482; Катибов М.И., Богданов А.Б. Перинеальная уретростомия: результаты, клинико-статистические и терминологические аспекты. Урология. 2022;(2):113-120. DOI:10.18565/urology.2022.2.113-120; Глухов В.П., Ильяш А.В., Митусов В.В., Сизякин Д.В., Коган М.И. Роль перинеальной уретростомии в лечении пациентов со стриктурами спонгиозной уретры. Вестник урологии. 2022;10(2):87-98. DOI:10.21886/2308-6424-2022-10-2-87-98; Verla W, Oosterlinck W, Waterloos M, Spinoit AF, Lumen N. Perineal Urethrostomy for Complicated Anterior Urethral Strictures: Indications and Patient's Choice. An Analysis at a Single Institution. Urology. 2020;138:160-165. DOI:10.1016/j.urology.2019.11.064; Arya MC, Singhal A, Vasudeo V, Shyoran Y, Gandhi A, Maan R, Sonwal M. Perineal urethrostomy: A single-stage viable option for complex anterior urethral strictures. Urol Ann. 2021;13(2):142-149. DOI:10.4103/UA.UA_111_20; Yadav P, Danish N, Sureka SS, Rustagi S, Kapoor R, Srivastava A, Singh UP. Permanent perineal urethrostomy for anterior urethral strictures: A critical appraisal of long-term outcomes and erectile function. Turk J Urol. 2021;47(2):158-163. DOI:10.5152/tud.2020.20322; Abedi A, Razzaghi MR, Rahavian A, Hazrati E, Aliakbari F, Vahedisoraki V, Allameh F. Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article. J Lasers Med Sci. 2020;11(2):197-203. DOI:10.34172/jlms.2020.33; Yilmaz M, Esser J, Suarez-Ibarrola R, Gratzke C, Miernik A. Safety and Efficacy of Laser Enucleation of the Prostate in Elderly Patients – A Narrative Review. Clin Interv Aging. 2022;17:15-33. DOI:10.2147/CIA.S347698; Hartung FO, Kowalewski KF, von Hardenberg J, Worst TS, Kriegmair MC, Nuhn P, Herrmann TRW, Michel MS, Herrmann J. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2022;8(2):545-554. DOI:10.1016/j.euf.2021.03.024; https://www.urovest.ru/jour/article/view/827

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/827
https://doi.org/10.21886/2308-6424-2024-12-1-27-35

Antibiotic resistance of microorganisms isolated from the urine of patients before surgical treatment for benign prostatic hyperplasia: results from a 7-year single-center study ; Антибиотикорезистентность микроорганизмов, выделенных из мочи пациентов до хирургического лечения гиперплазии предстательной железы: данные 7-летнего многоцентрового исследования

Συγγραφείς: M. I. Kogan, V. L. Medvedev, Yu. L. Naboka, D. V. Sizyakin, S. N. Ivanov, G. A. Palaguta, I. A. Gudima, М. И. Коган, В. Л. Медведев, Ю. Л. Набока, Д. В. Сизякин, С. Н. Иванов, Г. А. Палагута, И. А. Гудима

Συνεισφορές: The research was supported by FASIE (No 19043GU/2023 dated February 21, 2024)., Исследование выполнено при финансовой поддержке Фонда содействия инновациям (№ 19043ГУ/2023 от 21 февраля 2024 года).

Πηγή: Urology Herald; Том 12, № 2 (2024); 23-32 ; Вестник урологии; Том 12, № 2 (2024); 23-32 ; 2308-6424 ; 10.21886/2308-6424-2024-12-2

Θεματικοί όροι: антибиотико-резистентность, BPH, transurethral resection of the prostate, TURP, urinary tract infections, UTI, antibiotic resistance, ДГПЖ, трансуретральная резекция предстательной железы, ТУРП, инфекции мочевых путей, ИМП

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/852/547; Hrbacek J, Tlaskal V, Cermak P, Hanacek V, Zachoval R. Bladder Microbiota Are Associated with Clinical Conditions That Extend beyond the Urinary Tract. Microorganisms. 2022;10(5):874. DOI:10.3390/microorganisms10050874; Naboka YL, Mavzyutov AR, Kogan MI, Gudima IA, Dzhalagoniya KT, Ivanov SN, Naber KG. The gene profile of Enterobacteriaceae virulence factors in relation to bacteriuria levels between the acute episodes of recurrent uncomplicated lower urinary tract infection. Expert Rev Anti Infect Ther. 2021;19(8):1061-1066. DOI:10.1080/14787210.2021.1866986; Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Saudi Pharm J. 2018;26(5):678-684. DOI:10.1016/j.jsps.2018.02.023; Коган М.И., Набока Ю.Л., Иванов С.Н. Факторы риска, антибиотикопрофилактика и лечение инфекции мочевых путей при трансуретральной хирургии гиперплазии простаты. Вестник урологии. 2022;10(2):99-108. DOI:10.21886/2308-6424-2022-10-2-99-108; Kot B, Grużewska A, Szweda P, Wicha J, Parulska U. Antibiotic Resistance of Uropathogens Isolated from Patients Hospitalized in District Hospital in Central Poland in 2020. Antibiotics (Basel). 2021;10(4):447. DOI:10.3390/antibiotics10040447; Иванов С.Н., Коган М.И., Набока Ю.Л., Медведев В.Л. Инфекционный фактор при трансуретральной хирургии доброкачественной гиперплазии простаты: систематический обзор и мета-анализ. Урология. 2023;(4):141-149. DOI:10.18565/urology.2023.4.141-149; Козлов Р.С., Меньшиков В.В., Михайлова В.С., Шуляк Б.Ф., Долгих Т.И., Круглов А.Н., Алиева Е.В., Маликова В.Е. Бактериологический анализ мочи. Клинические рекомендации. М.; 2014.; Agbugui JO, Obarisiagbon EO, Osaigbovo II. Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia. Niger J Surg. 2016;22(2):65-69. DOI:10.4103/1117-6806.177415; Behcet M, Avcioglu F. Causative Agents of Urinary Tract Infections in Elderly Men with Benign Prostatic Hyperplasia: a Microbiological Evaluation. Clin Lab. 2021;67(6). DOI:10.7754/Clin.Lab.2020.200940; Dybowski BA, Zapała P, Bres-Niewada E, Zapała Ł, Miązek-Zapała N, Poletajew S, Młynarczyk G, Radziszewski P. Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. BMC Infect Dis. 2018;18(1):590. DOI:10.1186/s12879-018-3507-9; Mishra PP, Prakash V, Singh K, Mog H, Agarwal S. Bacteriological Profile of Isolates From Urine Samples in Patients of Benign Prostatic Hyperplasia and or Prostatitis Showing Lower Urinary Tract Symptoms. J Clin Diagn Res. 2016;10(10):DC16-DC18. DOI:10.7860/JCDR/2016/21973.8734; https://www.urovest.ru/jour/article/view/852

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/852
https://doi.org/10.21886/2308-6424-2024-12-2-23-32

PSA density as a predictor of long-term infectious complications during transurethral resection of the prostate: determining an optimal cut-off value ; Плотность ПСА как предиктор отдалённых инфекционных осложнений при трансуретральной резекции простаты: определение оптимального порогового значения показателя

Συγγραφείς: S. N. Ivanov, M. I. Kogan, Yu. L. Naboka, V. L. Medvedev, G. A. Palaguta, С. Н. Иванов, М. И. Коган, Ю. Л. Набока, В. Л. Медведев, Г. А. Палагута

Πηγή: Urology Herald; Том 12, № 1 (2024); 19-26 ; Вестник урологии; Том 12, № 1 (2024); 19-26 ; 2308-6424 ; 10.21886/2308-6424-2024-12-1

Θεματικοί όροι: простатит, BPH, transurethral resection of the prostate gland, TURP, infectious complications, urinary tract infections, UTI, prostate-specific antigen density, PSA, pyelonephritis, epididymo-orchitis, prostatitis, ДГПЖ, трансуретральная резекция предстательной железы, ТУРП, инфекционные осложнения, инфекции мочевых путей, ИМП, плотность простатспецифического антигена, ПСА, пиелонефрит, эпидидимоорхит

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/826/530; Jo JK, Shinn SH, Kim KS, Moon HS. Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea. Int Neurourol J. 2021;25(4):347-354. DOI:10.5213/inj.2040412.206; Lin YH, Hou CP, Chen TH, Juang HH, Chang PL, Yang PS, Chen CL, Tsui KH. Transurethral resection of the prostate provides more favorable clinical outcomes compared with conservative medical treatment in patients with urinary retention caused by benign prostatic obstruction. BMC Geriatr. 2018;18(1):15. DOI:10.1186/s12877-018-0709-3; Vivien A, Lazard T, Rauss A, Laisné MJ, Bonnet F. Infection after transurethral resection of the prostate: variation among centers and correlation with a long-lasting surgical procedure. Association pour la Recherche en AnesthésieRéanimation. Eur Urol. 1998;33(4):365-369. DOI:10.1159/000019617; Guo RQ, Yu W, Meng YS, Zhang K, Xu B, Xiao YX, Wu SL, Pan BN. Correlation of benign prostatic obstruction-related complications with clinical outcomes in patients after transurethral resection of the prostate. Kaohsiung J Med Sci. 2017;33(3):144-151. DOI:10.1016/j.kjms.2017.01.002; Mayer EK, Kroeze SG, Chopra S, Bottle A, Patel A. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012;110(11):1595-1601. DOI:10.1111/j.1464-410X.2012.11119.x; Osman T, ElSaeed KO, Youssef HA, Shabayek M, Emam A, Hussein MS. Evaluation of the risk factors associated with the development of post-transurethral resection of the prostate persistent bacteriuria. Arab J Urol. 2017;15(3):260-266. DOI:10.1016/j.aju.2017.05.004; El Basri A, Petrolekas A, Cariou G, Doublet JD, Hoznek A, Bruyere F. Clinical significance of routine urinary bacterial culture after transurethral surgery: results of a prospective multicenter study. Urology. 2012;79(3):564-569. DOI:10.1016/j.urology.2011.11.018; Girou E, Rioux C, Brun-Buisson C, Lobel B; Infection Committee of the French Association of Urology. The postoperative bacteriuria score: a new way to predict nosocomial infection after prostate surgery. Infect Control Hosp Epidemiol. 2006;27(8):847-854. DOI:10.1086/506398; Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG; Working Group "Urological Infections" of German Society of Urology. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/ sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Eur Urol. 2005;47(4):549-556. DOI:10.1016/j.eururo.2005.01.004; Коган М.И., Набока Ю.Л., Иванов С.Н. Факторы риска, антибиотикопрофилактика и лечение инфекции мочевых путей при трансуретральной хирургии гиперплазии простаты. Вестник урологии. 2022;10(2):99-108. DOI:10.21886/2308-6424-2022-10-2-99-108; Коган М.И., Набока Ю.Л., Иванов С.Н. Оценка инфекционного фактора при трансуретральной хирургии гиперплазии простаты. Вестник урологии. 2021;9(3):79-91. DOI:10.21886/2308-6424-2021-9-3-79-91; Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. USA, Rockville: Agency for Healthcare Research and Quality (US); 2018.; Arjunlal TS, Deepanjali S, Manikandan R, Medha R. Frequency and clinical significance of prostatic involvement in men with febrile urinary tract infection: a prospective observational study. F1000Res. 2020;9:617. DOI:10.12688/f1000research.24094.3; Иванов С.Н., Коган М.И., Набока Ю.Л., Медведев В.Л. Инфекционный фактор при трансуретральной хирургии доброкачественной гиперплазии простаты: систематический обзор и мета-анализ. Урология. 2023;(4):141-149. DOI:10.18565/urology.2023.4.141-149; Coric J, Mujic J, Kucukalic E, Ler D. Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. Open Biochem J. 2015;9:34-36. DOI:10.2174/1874091X01509010034; https://www.urovest.ru/jour/article/view/826

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/826
https://doi.org/10.21886/2308-6424-2024-12-1-19-26

Comparison of en-bloc resection of the bladder wall and tumor with standard transurethral bladder resection in treatment of non-muscle invasive bladder cancer ; Сравнение en-bloc резекции стенки мочевого пузыря с опухолью со стандартной трансуретральной резекцией мочевого пузыря при лечении немышечно-инвазивного рака мочевого пузыря

Συγγραφείς: S. V. Kotov, R. I. Guspanov, S. A. Pulbere, A. L. Khachatryan, Sh. M. Sargsian, Yu. P. Kraev, D. A. Samoylov, С. В. Котов, Р. И. Гуспанов, С. А. Пульбере, А. Л. Хачатрян, Ш. М. Саргсян, Ю. П. Краев, Д. А. Самойлов

Πηγή: Cancer Urology; Том 20, № 2 (2024); 101-109 ; Онкоурология; Том 20, № 2 (2024); 101-109 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: трансуретральная резекция стенки мочевого пузыря с опухолью, non-muscle-invasive bladder cancer, treatment of non-muscle invasive bladder cancer, transurethral resection of the bladder wall with a tumor, немышечно-инвазивный рак мочевого пузыря, лечение немышечно-инвазивного рака мочевого пузыря

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1824/1537; EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023.; Fankhauser C.D., Wettstein M.S., Afferi L. et al. En Bloc Resection of Bladder Tumor-Is It the Way Forward? Front Surg 2021;8:685506. DOI:10.3389/fsurg.2021.685506; Yang H., Lin J., Gao P. et al. Is the en bloc transurethral resection more effective than conventional transurethral resection for nonmuscle-invasive bladder cancer? A systematic review and metaanalysis. Urol Int 2020;104(5–6):402–9. DOI:10.1159/000503734; Mori K., D’Andrea D., Enikeev D.V. et al. En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature. Curr Opin Urol 2020;30(1):41–7. DOI:10.1097/MOU.0000000000000697; Мартов А.Г., Ергаков Д.В., Байков Н.А. Трансуретральная гольмиевая резекция мочевого пузыря с применением техники единого блока. Медицинский вестник Башкортостана 2015;(57).; Котов С.В., Гуспанов Р.И., Хачатрян А.Л. и др. Применение en-bloc резекции стенки мочевого пузыря с опухолью при лечении немышечно-инвазивного рака мочевого пузыря. Онкоурология 2022;18(4):120–8. DOI:10.17650/1726-9776-2022-18-4-120-128; Martin-Doyle W., Leow J.J., Orsola A. et al. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015;33(6):643–50. DOI:10.1200/JCO.2014.57.6967; Koch M.O., Smith Jr. Natural history and surgical management of superficial bladder cancer (stages Ta/T1/CIS). In: Comprehensive Textbook of Genitourinary Oncology. Chapter 26. Lippincott Williams and Wilkins, Baltimore, 1996. Pp. 405–15.; Rolevich A., Minich A., Nabebina T. et al. Surgeon has a major impact on long-term recurrence risk in patients with nonmuscle invasive bladder cancer. Cent European J Urol 2016;69(2):170–7. DOI:10.5173/ ceju.2016.795; Zhang D., Yao L., Yu S. et al. Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. World J Surg Oncol 2020;18(1):4. DOI:10.1186/s12957-019-1776-4; Herr H.W., Donat S.M. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1197–8. DOI:10.1016/S0022-5347(18)33065-9; Woldu S.L., Bagrodia A., Lotan Y. Guideline of guidelines: nonmuscle-invasive bladder cancer. BJU Int 2017;119(3):371–80.; Chen X., Liao J., Chen L. et al. En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscleinvasive bladder cancer: a randomized controlled trial. World J Urol 2015;33:989–95. DOI:10.1007/s00345-014-1342-1; Sureka S., Agarwal V., Agnihotri S. et al. Is en-bloc transurethral resection of bladder tumor for non-muscle invasive bladder carcinoma better than conventional technique in terms of recurrence and progression? A prospective study. Indian J Urol 2014;30(2):144–9. DOI:10.4103/0970-1591.126887; Kramer M., Altiery V., Hurl R. et al. Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus 2017;3(6):567–76. DOI:10.1016/j.euf.2016.12.004; https://oncourology.abvpress.ru/oncur/article/view/1824

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1824
https://doi.org/10.17650/1726-9776-2024-20-2-101-109

Рак мочевого пузыря

Συγγραφείς: А. А. Румянцев, П. В. Булычкин, М. И. Волкова, О. А. Гладков, Р. А. Зуков, В. Б. Матвеев, Д. А. Носов

Πηγή: Malignant tumours; Том 14, № 3s2-2 (2024); 221-241 ; Злокачественные опухоли; Том 14, № 3s2-2 (2024); 221-241 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: иммунотерапия, трансуретральная резекция, внутрипузырная терапия, радикальная цистэктомия, тримодальная терапия, химиотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1390/995; https://www.malignanttumors.org/jour/article/view/1390

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1390
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-09

Infravesical Obstruction in a Boy with Orthotopic Ureterocele: Clinical Case ; Инфравезикальная обструкция у мальчика с ортотопическим уретероцеле: клинический случай

Συγγραφείς: Anastasia A. Bebenina, Olga G. Mokrushina, Marina V. Levitskaya, Vasiliy S. Shumikhin, Nadezhda N. Erokhina, А. А. Бебенина, О. Г. Мокрушина, М. В. Левитская, В. С. Шумихин, Н. О. Ерохина

Συνεισφορές: Not specified, Отсутствует

Πηγή: Current Pediatrics; Том 22, № 2 (2023); 202-206 ; Вопросы современной педиатрии; Том 22, № 2 (2023); 202-206 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: трансуретральная резекция, ureterocele, infravesical obstruction, lower urinary tract dysfunction, transurethral resection, уретероцеле, инфравезикальная обструкция, дисфункция нижних мочевых путей

Περιγραφή αρχείου: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3187/1292; Baskin LS, Kogan BA, Stock JA. Handbook of Pediatric Urology. 3rd ed. 2019. pp. 124–127.; Merlini E, Lelli Chiesa P. Obstructive ureterocele-an ongoing challenge. World J Urol. 2004;22(2):107–114. doi: https://doi.org/10.1007/s00345-004-0407-y; Uson AC, Lattimer JK, Melicow MM. Ureteroceles in infants and children: A report based on 44 cases. Pediatrics. 1961;27(6): 971–983. doi: https://doi.org/10.1542/peds.27.6.971; Radmayr C, Bogaert G, Dogan HS, et al. EAU Guidlines on Paediatric Uroligy. Eur Urol. 2001;40(5):589–599. doi: https://doi.org/10.1159/000049841; Şimşek ÖÖ, Tiryaki S., Erfidan G, et al. Evaluation of Pediatric Patients with a Diagnosis of Ureterocele. Pediatr Rep. 2022;14(4):533–537. doi: https://doi.org/10.3390/pediatric14040062; Peters C, Schlussel RN, Mendelsohn C. Ectopic Ureter, Ureterocele, and Ureteral Anomalies. Campbell-Walsh Urology. 2012;3236–3266.e3. doi: https://doi.org/10.1016/B978-1-4160-6911-9.00121-3; Меновщикова Л.Б., Рудин Ю.Э., Гарманова Т.Н., Шадер кина В.А. Клинические рекомендации по детской урологии-андрологии. — М.: Изд-во «Перо»; 2015. — 240 с.; Mohta А, Upreti L. Cecoureterocele. Indian Pediatr. 2010; 47(6):522–523.; Tekgul S, Riedmiller H, Gerharz P, et al. Pediatric Urology. ESPU; 2011.; Partin AW, Dmochowski RR, Kavoussi LR, et al. Campbell Walsh Wein Urology. In 3 vol. 12th ed. Elsevier; 2020.; Timberlake MT, Corbett ST. Minimally invasive Techniques for management of the ureterocele and ectopic ureter: upper tract versus lower tract approach. Urol Clin North Am. 2015;42(1):61–76. doi: https://doi.org/10.1016/j.ucl.2014.09.006

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/3187
https://doi.org/10.15690/vsp.v22i2.2564

Ejaculation-sparing enucleation of benign prostate hyperplasia: is it almost feasible? ; Эякуляторно-протективная энуклеация доброкачественной гиперплазии предстательной железы: это вообще возможно?

Συγγραφείς: A. G. Martov, D. V. Ergakov, K. A. Asliev, N. A. Baykov, А. Г. Мартов, Д. В. Ергаков, К. А. Аслиев, Н. А. Байков

Πηγή: Urology Herald; Том 11, № 1 (2023); 59-69 ; Вестник урологии; Том 11, № 1 (2023); 59-69 ; 2308-6424 ; 10.21886/2308-6424-2023-11-1

Θεματικοί όροι: опросники, enucleation, thulium, antegrade ejaculation, transurethral prostate resection, quality of life, surveys and questionnaires, энуклеация, тулий, антеградная эякуляция, трансуретральная резекция простаты, качество жизни

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/670/446; Мартов А.Г., Меринов Д.С., Корниенко С.И. Гущин Б.Л., Ергаков Д.В., Мустафаев Э.М., Борисенко Е.А. Послеоперационные урологические осложнения трансуретральных операций на предстательной железе. Урология. 2006;(2):25-32. PMID: 16708585; Alloussi SH, Lang C, Eichel R, Alloussi S. Ejaculationpreserving transurethral resection of prostate and bladder neck: short- and long-term results of a new innovative resection technique. J Endourol. 2014;28(1):84-9. DOI:10.1089/end.2013.0093; Gild P, Dahlem R, Pompe RS, Soave A, Vetterlein MW, Ludwig TA, Maurer V, Marks P, Ahyai SA, Chun FK, Lenke L, Ernst T, Fisch M, Rink M, Meyer CP, Becker A. Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)-Impact on sexual function and evaluation of patient bother using validated questionnaires. Andrology. 2020;8(6):1779-1786. DOI:10.1111/andr.12887; Мартов А.Г., Ергаков Д.В., Турин Д.Е., Андронов А.С. Биполярная и лазерная энуклеация ДГПЖ больших размеров. Урология. 2020;(1):59-63. DOI:10.18565/urology.2020.1.59-63; Мартов А.Г., Ергаков Д.В. Возрастной андрогенный дефицит и ДГПЖ: как улучшить сексуальную реабилитацию пациентов после трансуретральных операций? Урология. 2016;(6):110-117. eLIBRARY ID: 28129929; EDN: VIAGXC; Herrmann TRW, Wolters M. Transurethral anatomical enucleation of the prostate with Tm:YAG support (ThuLEP): Evolution and variations of the technique. The inventors' perspective. Andrologia. 2020;52(8):e13587. DOI:10.1111/and.13587; Kim M, Song SH, Ku JH, Kim HJ, Paick JS. Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. Int J Impot Res. 2015;27(1):20-4. DOI:10.1038/ijir.2014.22; Xu C, Xu Z, Lin C, Feng S, Sun M, Chen J, Zheng Y. Holmium Laser Enucleation of the Prostate: Modified Two-Lobe Technique versus Traditional Three-Lobe Technique-A Randomized Study. Biomed Res Int. 2019;2019:3875418. DOI:10.1155/2019/3875418; Leonardi R. The LEST technique: Treatment of prostatic obstruction preserving antegrade ejaculation in patients with benign prostatic hyperplasia. Arch Ital Urol Androl. 2019;91(1):35-42. DOI:10.4081/aiua.2019.1.35; Мартов А.Г., Андронов А.С., Дутов С.В., Байков Н.А. Эякуляторно-протективная трансуретральная резекция предстательной железы. Урология. 2014;(4):69-75. eLIBRARY ID: 22370362; EDN: SVNUNJ; Попов С.В., Скрябин О.Н., Орлов И.Н., Гринь Е.А., Топузов Т.М., Кызласов П.С., Малевич С.М., Сушина И.В., Вязовцев П.В. Копулятивная функция у пациентов, перенесших трансуретральные и эндовидеохирургические вмешательства по поводу ДГПЖ. Экспериментальная и клиническая урология. 2017;(4):42-48. eLIBRARY ID: 32362469; EDN: YNJPHC; https://www.urovest.ru/jour/article/view/670

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/670
https://doi.org/10.21886/2308-6424-2023-11-1-59-69

Diagnostika i lechenie detey s klapanami zadney chasti uretry ; Диагностика и лечение детей с клапанами задней части уретры

Συγγραφείς: Ibodov K.I., Rofiev R.R., Sayedov K.M., Asadov S.K.

Πηγή: Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care; Vol 13 (2023): Supplement; 69 ; Российский вестник детской хирургии, анестезиологии и реаниматологии; Vol 13 (2023): Supplement; 69 ; 2587-6554 ; 2219-4061 ; 10.17816/psaic.2023

Θεματικοί όροι: клапан задней части уретры, трансуретральная резекция, гольмиевый лазер

Περιγραφή αρχείου: application/pdf

Relation: https://rps-journal.ru/jour/article/view/1635/1598

Διαθεσιμότητα: https://rps-journal.ru/jour/article/view/1635
https://doi.org/10.17816/psaic1635

Рак мочевого пузыря

Συγγραφείς: О. А. Гладков, П. В. Булычкин, М. И. Волкова, Р. А. Зуков, В. Б. Матвеев, Д. А. Носов

Πηγή: Malignant tumours; Том 13, № 3s2-1 (2023); 620-639 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 620-639 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: иммунотерапия, трансуретральная резекция, внутрипузырная терапия, радикальная цистэктомия, тримодальная терапия, химиотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1234/868; https://www.malignanttumors.org/jour/article/view/1234

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1234
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-620-639

Personalized Approach to the Surgical Treatment of Benign Prostatic Hyperplasia by Bipolar Transurethral Resection of the Prostate ; Персонифицированный подход к хирургическому лечению доброкачественной гиперплазии предстательной железы методом биполярной трансуретральной резекции простаты

Συγγραφείς: I. A. Chekhonatskii, O. B. Loran, И. А. Чехонацкий, О. Б. Лоран

Συνεισφορές: This work is not funded, Данная работа не финансировалась

Πηγή: Creative surgery and oncology; Том 13, № 2 (2023); 125-130 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 125-130 ; 2076-3093 ; 2307-0501

Θεματικοί όροι: холиноблокаторы, bipolar transurethral resection of the prostate, preoperative management, postoperative complications, personalized approach, persistent irritative symptoms, alpha-blockers, anticholinergics, биполярная трансуретральная резекция простаты, предоперационное ведение больного, послеоперационные осложнения, персонифицированный подход, персистирующие ирридативные симптомы, альфа-адреноблокаторы

Περιγραφή αρχείου: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/809/546; Чехонацкий И. А., Лоран О. Б., Лукьянов И. В., Серегин А. В., Морозов А. Д. Интравезикальная простатическая протрузия как предиктор функционального результата хирургического метода лечения доброкачественной гиперплазии предстательной железы. Урология. 2022; 3: 58–62. DOI:10.18565/urology.2020.1.103-109; Аляев Ю. Г., Рапопорт Л. М., Винаров А. З., Цариченко Д. Г., Фиев Д. Н., Бушуев В. О. Особенности предоперационной подготовки и лечения при гиперплазии простаты больших размеров. Андрология и генитальная хирургия. 2009; 10 (1): 50–3.; Ергаков Д. В., Мартов А. Г., Турин Д. Е., Андронов А. С. Симптомы нижних мочевыводящих путей после трансуретральной резекции предстательной железы. Урология. 2020; 1: 103–9. DOI:10.18565/urology.2020.1.103-109; Лоран О. Б., Чехонацкий И. А., Лукьянов И. В. Оценка эффективности эндоскопических методов хирургического лечения доброкачественной гиперплазии простаты на основе результатов данных международных мета-анализов. Саратовский научно-медицинский журнал. 2021; 17 (2): 209–13.; Пушкарь Д. Ю., Раснер П. И., Абоян И. А., Асфандияров Ф. Р., Котов С. В., Коган М. И. и др. СНМП/ДГПЖ — кто лечит? Результаты эпидемиологического исследования. Урология. 2019; 1: 5–15. DOI:10.18565/urology.2019.16.5-15; Deng Y., Zheng Z., Cheng S., Lin Y., Wang D., Yin P., et al. The factors associated with nosocomial infection in elderly hip fracture patients: gender, age, and comorbidity. Int Orthop. 2021; 45 (12): 3201–9. DOI:10.1007/s00264-021-05104-3; Tan Y. G., Teo J. S., Kuo T. L. C., Guo L., Shi L., Shutchaidat V., et al. A systemic review and meta-analysis of transabdominal intravesical prostatic protrusion assessment in determining bladder outlet obstruction and unsuccessful trial without catheter. Eur Urol Focus. 2022; 8 (4): 1003–14. DOI:10.1016/j.euf.2021.09.016; Мартов А. Г., Турин Д. Е., Ергаков Д. В., Андронов А. С., Камалов А. А. Выбор медикаментозной терапии у пациентов после биполярной трансуретральной резекции предстательной железы в зависимости от ее исходных размеров. Экспериментальная и клиническая урология. 2019; 2: 70–9. DOI:10.29188/2222-8543-2019-11-2-70-78; Ергаков Д. В., Мартов А. Г. Комбинированная терапия расстройств мочеиспускания после трансуретральной резекции предстательной железы. Урология. 2018; 1: 62–70. DOI:10.18565/urology.2018.1.62-70; Цуканов А. Ю., Ахметов Д. С., Новиков А. А., Негров Д. А., Путинцева А. Р. Профилактика инкрустации и образования биопленок на поверхности мочеточникового стента. Часть 1. Экспериментальная и клиническая урология. 2020; 3: 176–81. DOI:10.29188/2222-8543-2020-12-3-176-181; Serlin D. C., Heidelbaugh J. J., Stoffel J. T. Urinary retention in adults: evaluation and initial management. Am Fam Physician. 2018; 98 (8): 496–503. PMID: 30277739.; He Y. L., Chen Y., Wen Y. B., Zhai R. Q., Ma Y., Wang J. J., et al. Changes in bladder function with time following cystostomy in rats. Neurourol Urodyn. 2020; 39 (2): 565–75. DOI:10.1002/nau.24241; Forsvall A., Jönsson H., Wagenius M., Bratt O., Linder A. Rate and characteristics of infection after transrectal prostate biopsy: a retrospective observational study. Scand J Urol. 2021; 55 (4): 317–23. DOI:10.1080/21681805.2021.1933169; Ергаков Д. В., Мартов А. Г., Аслиев К. А. Клиническое использование цитомединов у пациентов с заболеваниями предстательной железы. Экспериментальная и клиническая урология. 2021; 14 (3): 134–41. DOI:10.29188/2222-8543-2021-14-3-136-140; Григорьев Н. А., Абдуллин И. И., Логинов А. В., Жиляев Е. В. Применение фосфомицина в антибиотикопрофилактике инфекционных осложнений биопсии предстательной железы. Медицинский совет. 2022; 16 (6): 68–73. DOI:10.21518/2079-701X-2022-16-6-68-73; https://www.surgonco.ru/jour/article/view/809

Διαθεσιμότητα: https://www.surgonco.ru/jour/article/view/809
https://doi.org/10.24060/2076-3093-2023-13-2-125-130

Retrospective Cohort Trial of the Effectiveness of Plasma Surgery for Benign Prostatic Hyperplasia of Large and Giant Sizes ; Ретроспективное когортное исследование эффективности плазменной хирургии доброкачественной гиперплазии простаты больших и гигантских размеров

Συγγραφείς: Sevryukov F.A.

Συνεισφορές: 1

Πηγή: Annals of the Russian academy of medical sciences; Vol 78, No 1 (2023); 62-76 ; Вестник Российской академии медицинских наук; Vol 78, No 1 (2023); 62-76 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.781

Θεματικοί όροι: benign prostatic hyperplasia, prostate adenoma, prostate transurethral resection, laser surgery, prostatectomy, доброкачественная гиперплазия простаты, аденома простаты, трансуретральная резекция простаты, лазерная хирургия, простатэктомия

Περιγραφή αρχείου: application/pdf

Relation: https://vestnikramn.spr-journal.ru/jour/article/view/2082/1756; https://vestnikramn.spr-journal.ru/jour/article/view/2082/1770; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2462; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2463; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2464; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2609; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2610; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2695; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2696; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/2697; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/54167; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/54186; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/54187; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/54197; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/2082/54198

Διαθεσιμότητα: https://vestnikramn.spr-journal.ru/jour/article/view/2082
https://doi.org/10.15690/vramn2082

Recent advances in transurethral resection of bladder tumors ; Новейшие достижения в трансуретральной резекции стенки мочевого пузыря с опухолью

Συγγραφείς: D. I. Babaevskaya, A. K. Bazarkin, M. S. Taratkin, D. V. Enikeev, Д. И. Бабаевская, А. К. Базаркин, М. С. Тараткин, Д. В. Еникеев

Πηγή: Urology Herald; Том 10, № 1 (2022); 96-103 ; Вестник урологии; Том 10, № 1 (2022); 96-103 ; 2308-6424 ; 10.21886/2308-6424-2022-10-1

Θεματικοί όροι: обзор, transurethral resection of bladder tumor, non-muscle invasive bladder cancer, review, трансуретральная резекция стенки мочевого пузыря с опухолью, мышечно-неинвазивный рак мочевого пузыря

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/527/387; Capogrosso P, Capitanio U, Ventimiglia E, Boeri L, Briganti A, Colombo R, Montorsi F, Salonia A. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality? J Endourol. 2016;30(4):400-5. DOI:10.1089/end.2015.0591; Mariappan P, Zachou A, Grigor KM; Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843-9. DOI:10.1016/j.eururo.2009.05.047; Ontario Health (Quality). Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment. Ont Health Technol Assess Ser. 2021;21(12):1-123. PMID: 34484486; PMCID: PMC8382283; Bach T, Muschter R, Herrmann TR, Knoll T, Scoffone CM, Laguna MP, Skolarikos A, Rischmann P, Janetschek G, De la Rosette JJ, Nagele U, Malavaud B, Breda A, Palou J, Bachmann A, Frede T, Geavlete P, Liatsikos E, Jichlinski P, Schwaibold HE, Chlosta P, Martov AG, Lapini A, Schmidbauer J, Djavan B, Stenzl A, Brausi M, Rassweiler JJ. Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. BJU Int. 2015;115(1):14-23. DOI:10.1111/bju.12664; Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846-54. DOI:10.1016/j.eururo.2013.03.059; Schraml J, Silva JDC, Babjuk M. Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection. Curr Opin Urol. 2018;28(6):591-597. DOI:10.1097/MOU.0000000000000542; Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR; Aberdeen Technology Assessment Review (TAR) Group. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011;27(1):3-10. DOI:10.1017/S0266462310001364; Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ; PC B302/01 Study Group. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178(1):62-7. DOI:10.1016/j.juro.2007.03.034; Gono K, Obi T, Yamaguchi M, Ohyama N, Machida H, Sano Y, Yoshida S, Hamamoto Y, Endo T. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt. 2004;9(3):568-77. DOI:10.1117/1.1695563; Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, Chen Q. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One. 2017;12(2):e0170819. DOI:10.1371/journal.pone.0170819; Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76(5):639-657. DOI:10.1016/j.eururo.2019.08.016; Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, Lam GW, Jensen JB. Comparison of White Light, Photodynamic Diagnosis, and Narrow-band Imaging in Detection of Carcinoma In Situ or Flat Dysplasia at Transurethral Resection of the Bladder: the DaBlaCa-8 Study. Urology. 2017;102:138-142. DOI:10.1016/j.urology.2016.11.032; EAU Guidelines: Non-muscle-invasive Bladder Cancer. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#note_125-128. Accessed December 7, 2020.; Cocci A, Patruno G, Gandaglia G, Rizzo M, Esperto F, Parnanzini D, Pietropaolo A, Principi E, Talso M, Baldesi R, Battaglia A, Shehu E, Carrobbio F, Corsaro A, La Rocca R, Marchioni M, Bianchi L, Miglioranza E, Mantica G, Martorana E, Misuraca L, Fontana D, Forte S, Napoli G, Russo GI; Senato degli Specializzandi Study Group. Urology Residency Training in Italy: Results of the First National Survey. Eur Urol Focus. 2018;4(2):280-287. DOI:10.1016/j.euf.2016.06.006; Poletajew S, Krajewski W, Kaczmarek K, Kopczyński B, Stamirowski R, Tukiendorf A, Zdrojowy R, Słojewski M, Radziszewski P. The Learning Curve for Transurethral Resection of Bladder Tumour: How Many is Enough to be Independent, Safe and Effective Surgeon? J Surg Educ. 2020;77(4):978-985. DOI:10.1016/j.jsurg.2020.02.010; Suarez-Ibarrola R, Soria F, Abufaraj M, D'Andrea D, Preto M, Gust KM, Briganti A, Shariat SF, Gontero P. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. BJU Int. 2019;123(4):646-650. DOI:10.1111/bju.14557; Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA 3rd, McKiernan J, Catto J, Babjuk M, Soloway M. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol. 2021;4(1):12-19. DOI:10.1016/j.euo.2020.06.010; Kawada T, Ebihara K, Suzuki T, Imai K, Yamanaka H. A new technique for transurethral resection of bladder tumors: rotational tumor resection using a new arched electrode. J Urol. 1997;157(6):2225-6. PMID: 9146621; Hurle R, Casale P, Lazzeri M, Paciotti M, Saita A, Colombo P, Morenghi E, Oswald D, Colleselli D, Mitterberger M, Kunit T, Hager M, Herrmann TRW, Lusuardi L. En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study. World J Urol. 2020;38(3):703-708. DOI:10.1007/s00345-019-02805-8; Hayashida Y, Miyata Y, Matsuo T, Ohba K, Sakai H, Taba M, Naito S, Taniguchi K. A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer. BMC Urol. 2019;19(1):56. DOI:10.1186/s12894-019-0486-0; Zhang KY, Xing JC, Li W, Wu Z, Chen B, Bai DY. A novel transurethral resection technique for superficial bladder tumor: retrograde en bloc resection. World J Surg Oncol. 2017;15(1):125. DOI:10.1186/s12957-017-1192-6; Cheng YY, Sun Y, Li J, Liang L, Zou TJ, Qu WX, Jiang YZ, Ren W, Du C, Du SK, Zhao WC. Transurethral endoscopic submucosal en bloc dissection for nonmuscle invasive bladder cancer: A comparison study of HybridKnife-assisted versus conventional dissection technique. J Cancer Res Ther. 2018;14(7):1606-1612. DOI:10.4103/jcrt.JCRT_786_17; Zhang D, Yao L, Yu S, Cheng Y, Jiang J, Ma Q, Yan Z. Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. World J Surg Oncol. 2020;18(1):4. DOI:10.1186/s12957-019-1776-4; Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, Lee LS, Wei Y, Yuan Y, Yu CP, Chow WK, Poon DM, Chan R, Lai F, Ng CF, Breda A, Kramer MW, Malavaud B, Mostafid H, Herrmann T, Babjuk M. An International Collaborative Consensus Statement on En bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020;78(4):546-569. DOI:10.1016/j.eururo.2020.04.059; Fritsche HM, Otto W, Eder F, Hofstädter F, Denzinger S, Chaussy CG, Stief C, Wieland WF, Burger M. Water-jet-aided transurethral dissection of urothelial carcinoma: a prospective clinical study. J Endourol. 2011;25(10):1599-603. DOI:10.1089/end.2011.0042; Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. Urology. 2012;79(4):846-51. DOI:10.1016/j.urology.2011.08.081; Enikeev D, Taratkin M, Margulis V, Sorokin NI, Severgina L, Paramonova N, Kislyakov D, Kozlov V, Rapoport L, Shariat S, Glybochko P. Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. Bladder Cancer. 2020;6:1-10. DOI:10.3233/BLC-200275; Zhao C, Tang K, Yang H, Xia D, Chen Z. Bipolar Versus Monopolar Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: A Meta-Analysis. J Endourol. 2016;30(1):5-12. DOI:10.1089/end.2015.0410; Venkatramani V, Panda A, Manojkumar R, Kekre NS. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. 2014;191(6):1703-7. DOI:10.1016/j.juro.2013.12.004; Hashem A, Mosbah A, El-Tabey NA, Laymon M, Ibrahiem EH, Elhamid MA, Elshal AM. Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial. Eur Urol Focus. 2021;7(5):1035-1043. DOI:10.1016/j.euf.2020.12.003; Wolters M, Kramer MW, Becker JU, Christgen M, Nagele U, Imkamp F, Burchardt M, Merseburger AS, Kuczyk MA, Bach T, Gross AJ, Herrmann TR. Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. World J Urol. 2011;29(4):429-32. DOI:10.1007/s00345-011-0686-z; Teichmann HO, Herrmann TR, Bach T. Technical aspects of lasers in urology. World J Urol. 2007;25(3):221-5. DOI:10.1007/s00345-007-0184-5; Chen X, Liao J, Chen L, Qiu S, Mo C, Mao X, Yang Y, Zhou S, Chen J. En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscle-invasive bladder cancer: a randomized controlled trial. World J Urol. 2015;33(7):989-95. DOI:10.1007/s00345-014-1342-1; Enikeev D, Traxer O, Taratkin M, Okhunov Z, Shariat S. A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery. Curr Opin Urol. 2020;30(6):853-860. DOI:10.1097/MOU.0000000000000815; Taratkin M, Kovalenko A, Laukhtina E, Paramonova N, Spivak L, Wachtendorf LJ, Eminovic S, Afyouni AS, Okhunov Z, Karagezyan M, Mikhailov V, Strakhov Y, Herrmann TR, Enikeev D. Ex vivo study of Ho:YAG and thulium fiber lasers for soft tissue surgery: which laser for which case? Lasers Med Sci. 2022;37(1):149-154. DOI:10.1007/s10103-020-03189-7; Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuardi L, Janetschek G, Hurle R, Wolters M, Abbas M, von Klot CA, Leitenberger A, Riedl M, Nagele U, Merseburger AS, Kuczyk MA, Babjuk M, Herrmann TR. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol. 2015;33(12):1937-43. DOI:10.1007/s00345-015-1568-6; Mundhenk J, Alloussi SH, Miller F, Hennenlotter J, Gakis G, Schilling D, Stenzl A, Schwentner C. En-bloc resection of non-muscle invasive bladder tumours with the combination instrument HybridKnife®. Eur Urol Suppl 2013;12:eV59. DOI:10.1016/S1569-9056(13)61642-5; Nagele U, Kugler M, Nicklas A, Merseburger AS, Walcher U, Mikuz G, Herrmann TR. Waterjet hydrodissection: first experiences and short-term outcomes of a novel approach to bladder tumor resection. World J Urol. 2011;29(4):423-7. DOI:10.1007/s00345-011-0653-8; Becker B, Enikeev D, Glybochko P, Rapoport L, Taratkin M, Gross AJ, Vinnichenko V, Herrmann TRW, Netsch C. Effect of optical fiber diameter and laser emission mode (cw vs pulse) on tissue damage profile using 1.94 µm Tm:fiber lasers in a porcine kidney model. World J Urol. 2020;38(6):1563-1568. DOI:10.1007/s00345-019-02944-y; https://www.urovest.ru/jour/article/view/527

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/527
https://doi.org/10.21886/2308-6424-2022-10-1-96-103

Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer ; Лабораторные предикторы ответа на внутрипузырную БЦЖ-терапию у пациентов с немышечно-инвазивным раком мочевого пузыря

Συγγραφείς: S. Yu. Konyashkina, S. A. Reva, S. B. Petrov, С. Ю. Коняшкина, С. А. Рева, С. Б. Петров

Πηγή: Urology Herald; Том 10, № 4 (2022); 155-164 ; Вестник урологии; Том 10, № 4 (2022); 155-164 ; 2308-6424 ; 10.21886/2308-6424-2022-10-4

Θεματικοί όροι: биомаркеры, bladder cancer, non-muscle-invasive cancer, transurethral resection, BCG therapy, biomarkers, рак мочевого пузыря, немышечно-инвазивный рак, трансуретральная резекция, БЦЖ-терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/615/424; Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. https://doi.org/10.1016/j.eururo.2021.08.010; Balasubramanian A, Gunjur A, Weickhardt A, Papa N, Bolton D, Lawrentschuk N, Perera M. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol. 2022;40(5):1111-1124. https://doi.org/10.1007/s00345-021-03908-x; Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-3. https://doi.org/10.1016/s0022-5347(17)58737-6; Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-56. https://doi.org/10.1016/j.eururo.2009.04.038; Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209-16. https://doi.org/10.1046/j.1464-410x.2001.02306.x; Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-23. https://doi.org/10.1016/j.urology.2005.12.014; Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-90. https://doi.org/10.1111/j.1464-410x.2003.04655.x; Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan;169(1):90-5. https://doi.org/10.1097/01.ju.0000039680.90768.b3; Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-70. https://doi.org/10.1097/01.ju.0000034450.80198.1c; Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014;11(3):153-62. https://doi.org/10.1038/nrurol.2014.15; Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer. 2009;124(12):2899-904. https://doi.org/10.1002/ijc.24258; Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012;187(3):862-7. https://doi.org/10.1016/j.juro.2011.10.144; Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016;117(5):754-60. https://doi.org/10.1111/bju.13186; Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol. 2016;69(2):197-200. https://doi.org/10.1016/j.eururo.2015.06.023; Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol. 2002 Jan;167(1):364-7. PMID: 11743357; Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S, Ohmoto Y, Naito K. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003 Aug;52(8):481-6. https://doi.org/10.1007/s00262-003-0384-9; de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol. 1996;155(2):477-82. PMID: 8558640; Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol. 2000;164(6):2129-33. PMID: 11061941; Sagnak L, Ersoy H, Ozok U, Senturk B, Ercil H, Bahar G, Ozturk E. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer. 2009;7(2):E16-23. https://doi.org/10.3816/CGC.2009.n.016; Luo Y, Han R, Evanoff DP, Chen X. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol. 2010;160(3):359-68. https://doi.org/10.1111/j.1365-2249.2010.04105.x; Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG, Ficarra V, Malossini G, Bartoletti R. Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med. 2012;4(3):459-464. https://doi.org/10.3892/etm.2012.634; Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer. 2003;89(12):2312-9. https://doi.org/10.1038/sj.bjc.6601474; Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner A. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget. 2016;7(26):39916-39930. https://doi.org/10.18632/oncotarget.9537; Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, Ochkur SI, Jacobsen EA, Hou YX, Andrews PE, Colby TV, Lee NA, Lee JJ. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol. 2014;32(1):45.e23-30. https://doi.org/10.1016/j.urolonc.2013.06.008; Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? Int Braz J Urol. 2019;45(2):315-324. https://doi.org/10.1590/S1677-5538.IBJU.2018.0249; Akan S, Ediz C, Sahin A, Tavukcu HH, Urkmez A, Horasan A, Yilmaz O, Verit A. Can the systemic immune inflammation index be a predictor of BCG response in patients with high-risk non-muscle invasive bladder cancer? Int J Clin Pract. 2021;75(4):e13813. https://doi.org/10.1111/ijcp.13813; Elsawy AA, Abol-Enein H, Laymon M, Ahmed AE, Essam A, Hamam ET, Zidan AA, Zahran MH, Shokeir AA, Awadalla A. Predictive value of immunological markers after bacille Calmette-Guérin induction in bladder cancer. BJU Int. 2022;130(4):444-453. https://doi.org/10.1111/bju.15582; Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol. 2009;56(5):829-36. https://doi.org/10.1016/j.eururo.2008.09.062; Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014;65(1):218-26. https://doi.org/10.1016/j.eururo.2012.05.033; Malmström PU, Hemdan T, Segersten U. Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer. Urol Oncol. 2017;35(8):532.e1-532.e6. https://doi.org/10.1016/j.urolonc.2017.03.010; Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2013;31(6):849-56. https://doi.org/10.1016/j.urolonc.2011.06.004; Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5. https://doi.org/10.1186/s12967-014-0373-0; Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207-12. https://doi.org/10.1016/j.coi.2011.12.009; Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-8. https://doi.org/10.1038/85330; Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267-79. https://doi.org/10.1016/j.eururo.2015.02.032; Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-62. https://doi.org/10.1038/nature13904; Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017;198(4):817-823. https://doi.org/10.1016/j.juro.2017.04.102; Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol. 2018;73(5):738-748. https://doi.org/10.1016/j.eururo.2017.10.003; Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 475-7. https://doi.org/10.1016/j.eururo.2005.12.031; Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992-1001. https://doi.org/10.1016/j.eururo.2007.10.006; Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423-30. https://doi.org/10.1016/j.eururo.2011.05.033; Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-203. https://doi.org/10.1016/j.juro.2009.07.016; https://www.urovest.ru/jour/article/view/615

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/615
https://doi.org/10.21886/2308-6424-2022-10-4-155-164

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021) ; Рекомендации по проведению тримодальной терапии рака мочевого пузыря (Невский консенсус 2021)

Συγγραφείς: R. V. Novikov, S. N. Novikov, A. I. Novikov, S. B. Petrov, S. A. Protsenko, V. V. Protoshchak, S. V. Popov, M. I. Shkolnik, E. S. Shpilenya, A. V. Kurenkov, V. P. Sokurenko, R. V. Orlova, А. K. Nosov, V. D. Korol, D. Kh. Latipova, Yu. V. Mikheeva, S. V. Kanaev, Р. В. Новиков, С. Н. Новиков, А. И. Новиков, С. Б. Петров, С. А. Проценко, В. В. Протощак, С. В. Попов, М. И. Школьник, Е. С. Шпиленя, А. В. Куренков, В. П. Сокуренко, Р. В. Орлова, А. К. Носов, В. Д. Король, Д. Х. Латипова, Ю. В. Михеева, С. В. Канаев

Πηγή: Cancer Urology; Том 18, № 2 (2022); 142-163 ; Онкоурология; Том 18, № 2 (2022); 142-163 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: химиотерапия, bladder cancer, muscle-invasive bladder cancer, trimodal therapy, organ-sparing treatment, transurethral resection, radiotherapy, chemotherapy, рак мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, тримодальная терапия, органосохраняющее лечение, трансуретральная резекция, лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1534/1375; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1087; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1088; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1089; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1090; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1091; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1092; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1093; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. DOI:10.3322/caac.21590; Cumberbatch M.G.K., Jubber I., Black P.C. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74(6):784–95. DOI:10.1016/j.eururo.2018.09.001; Rodrigues Pessoa R., Mueller A.C., Boxley P. et al. Systematic review and meta‑analysis of radiation therapy for high‑risk non‑muscle invasive bladder cancer. Urol Oncol 2021;39(11):786.e1–8. DOI:10.1016/j.urolonc.2021.03.009; Witjes J.A., Bruins H.M., Cathomas R. et al. European Association of Urology guidelines on muscle‑invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79(1):82–104. DOI:10.1016/j.eururo.2020.03.055; Chang S.S., Bochner B.H., Chou R. et al. Treatment of non‑metastatic muscle‑invasive bladder cancer: AUA/ASCO/ASTRO/ SUO Guideline. J Urol 2017;198(3):552–9. DOI:10.1016/j.juro.2017.04.086; Flaig T.W., Spiess P.E., Agarwal N. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(3):329–54. DOI:10.6004/jnccn.2020.0011; Witjes J.A., Babjuk M., Bellmunt J. et al. EAU‑ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multistakeholder effort: under the auspices of the EAU‑ESMO guidelines committees. Eur Urol 2020;77(2):223–50. DOI:10.1016/j.eururo.2019.09.035; Choi H., Park J.Y., Bae J.H., Tae B.S. Health‑related quality of life after radical cystectomy. Transl Androl Urol 2020;9(6):2997–3006. DOI:10.21037/tau.2020.02.01; Hautmann R.E., de Petriconi R.C., Volkmer В.G. Lessons learned from 1,000 neobladders: the 90‑day complication rate. J Urol 2010;184(3):990–4. DOI:10.1016/j.juro.2010.05.037; Nielsen M.E., Mallin K., Weaver M.A. et al. Association of hospital volume with conditional 90‑day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 2014;114(1):46–55. DOI:10.1111/bju.12566; Maffezzini M., Fontana V., Pacchetti A. et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl 2021;93(1):15–20. DOI:10.4081/aiua.2021.1.15; Novotny V., Froehner M., Koch R. et al. Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90‑day mortality after radical cystectomy. World J Urol 2016;34(8):1123–9. DOI:10.1007/s00345‑015‑1744‑8; Howlader N., Noone A.M., Krapcho M. et al. (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, Bethesda, MD. Available at: https://seer.cancer.gov/csr/1975_2014.; Kimura T., Ishikawa H., Kojima T. et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol 2020;50(10):1097–107. DOI:10.1093/jjco/hyaa155; Varughese M., Treece S., Drinkwater K.J. Radiotherapy management of muscle invasive bladder cancer: evaluation of a national cohort. Clin Oncol (R Coll Radiol) 2019;31(9):637–45. DOI:10.1016/j.clon.2019.04.009; Giacalone N.J., Shipley W.U., Clayman R.H. et al. Long‑term outcomes after bladderpreserving tri‑modality therapy for patients with muscle‑invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 2017;71(6):952–60. DOI:10.1016/j.eururo.2016.12.020; Francolini G., Borghesi S., Fersino S. et al. Treatment of muscle‑invasive bladder cancer in patients without comorbidities and fit for surgery: trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol 2021;159:103235. DOI:10.1016/j.critrevonc.2021.103235; Kulkarni G.S., Hermanns T., Wei Y. et al. Propensity score analysis of radical cystectomy versus bladder‑sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 2017;35(20):2299–305. DOI:10.1200/JCO.2016.69.2327; Ding H., Fan N., Ning Z., Ma D. Trimodal therapy vs. radical cystectomy for muscleinvasive bladder cancer: a meta‑analysis. Front Oncol 2020;10:564779. DOI:10.3389/fonc.2020.564779; Deuker M., Krimphove M.J., Stolzenbach L.F. et al. Radical cystectomy vs. multimodality treatment in T2N0M0 bladder cancer: a population‑based, agematched analysis. Clin Genitourin Cancer 2021;19(4):e264–71. DOI:10.1016/j.clgc.2021.03.010; Pieretti A., Krasnow R., Drumm M. et al. Complications and outcomes of salvage cystectomy after trimodality therapy. J Urol 2021;206(1):29–36. DOI:10.1097/JU.0000000000001696; Клинические рекомендации. Рак мочевого пузыря. Министерство здравоохранения Российской Федерации, 2020. Доступно по: https://cr.minzdrav.gov.ru.; Pieters B.R., van der Steen‑Banasik E., Smits G.A. et al. GEC‑ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle‑invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI:10.1016/j.radonc.2016.12.022; Der Steen‑Banasik E.V., Oosterveld B., Smits G. et al. Perpetual role of brachytherapy in organ‑sparing treatment for bladder cancer: a historical review. J Contemp Brachytherapy 2020;12(6): 618–28. DOI:10.5114/jcb.2020.101697; Heidegger I., Oberaigner W., Horninger W., Pichler R. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: a 10‑year single‑center experience. Urol Oncol 2017;35(4):152.e1–5. DOI:10.1016/j.urolonc.2016.11.004; Kumar A., Cherry D.R., Courtney P.T. et al. Outcomes for muscle‑invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans. Eur Urol Open Sci 2021;30:1–10. DOI:10.1016/j.euros.2021.05.009; Zhu Z., Zhao J., Li Y. et al. Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta‑analysis. PLoS One 2019;14(9):e0222223. DOI:10.1371/journal.pone.0222223; Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder‑sparing therapy. Eur Urol 2017;72(1):54–60. DOI:10.1016/j.eururo.2016.12.002; Bertz S., Wach S., Taubert H. et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch 2016;469(3):339–44. DOI:10.1007/s00428‑016‑1986‑x; Nagumo Y., Kojima T., Shiga M. et al. A single‑institute experience of trimodal bladder‑preserving therapy for histologic variants of urothelial carcinoma. Int J Clin Oncol 2020;25(2):354–61. DOI:10.1007/s10147‑019‑01553‑4; Khalifa J., Supiot S., Pignot G. et al. Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiother Oncol 2021;161:95–114. DOI:10.1016/j.radonc.2021.06.011; Premo C., Apolo A.B., Agarwal P.K., Citrin D.E. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am 2015;42(2):169–80. DOI:10.1016/j.ucl.2015.02.002; Hindson B.R., Turner S.L., Millar J.L. et al. RANZCR Faculty of Radiation Oncology Genito‑Urinary Group (FROGG). Australian & New Zealand Faculty of Radia‑tion Oncology Genito‑Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. J Med Imaging Radiat Oncol 2012;56(1):18–30. DOI:10.1111/j.1754‑9485.2011.02336.x; Gofrit O.N., Meirovitz A., Frank S. et al. Trimodal therapy in T2–4aN0M0 bladder cancer – how to select the best candidate? Cancer Med 2020;9(22):8491–7. DOI:10.1002/cam4.3478; Huddart R.A., Birtle A., Maynard L. et al. Clinical and patient‑reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 2017; 120(5): 639–50. DOI:10.1111/bju.13900; Freeman R.M. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(2):93–5. DOI:10.1007/s00192‑004‑1253‑6; Feldman A.S., Kulkarni G.S., Bivalacqua T.J. et al. Surgical challenges and considerations in tri‑modal therapy for muscle invasive bladder cancer. Urol Oncol 2021:S1078–1439(21)00012–0. DOI:10.1016/j.urolonc.2021.01.013; Nguyen E.K., Yu H., Pond G. et al. Outcomes of trimodality bladder‑sparing therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(4):122–9. DOI:10.5489/cuaj.5945; Russell C.M., Lebastchi A.H., Borza T. et al. The Role of transurethral resection in trimodal therapy for muscle‑invasive bladder cancer. Bladder Cancer 2016;2(4):381–94. DOI:10.3233/BLC‑160076; Ouzaid I., Panthier F., Hermieu J.F., Xylinas E. Contemporary surgical and technical aspects of transurethral resection of bladder tumor. Transl Androl Urol 2019;8(1):21–4. DOI:10.21037/tau.2019.01.04; Russo G.I., Sholklapper T.N., Cocci A. et al. Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non‑muscle invasive bladder cancer: a systematic review and lesion‑level diagnostic meta‑analysis. Cancers (Basel) 2021;13(17):4378. DOI:10.3390/cancers13174378; Babjuk M., Burger M., Capoun O. et al. European Association of Urology guidelines on non‑muscle‑invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2021;81(1):75–94. DOI:10.1016/j.eururo.2021.08.010; Новиков А.И., Леоненков Р.В., Темкин Д.Б. и др. Трансуретральная резекция карциномы мочевого пузыря, распространяющейся на устье мочеточника. Онкоурология 2021;17(2):104–11. DOI:10.17650/1726‑9776‑2021‑17‑2104‑111; Hafeez S., Lewis R., Hall E., Huddart R. RAIDER trial management group. Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image‑guided standard or dose‑escalated tumour boost radiotherapy (RAIDER). Clin Oncol (R Coll Radiol) 2021;33(6):e251–6. DOI:10.1016/j.clon.2021.02.012; Nolan C.P., Forde E.J. A review of the use of fiducial markers for image‑guided bladder radiotherapy. Acta Oncol 2016;55(5):533–8. DOI:10.3109/0284186X.2015.1110250; De Ridder M., Gerbrandy L.C., de Reijke T.M. et al. BioXmark® liquid fiducial markers for image‑guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol 2020;93(1111):20200241. DOI:10.1259/bjr.20200241; Russell B., Liedberg F., Khan М.S. et al. Systematic review and meta‑analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol 2020;3(2):239–49. DOI:10.1016/j.euo.2019.09.008; Yin M., Joshi M., Meijer R.P. et al. Chemotherapy for muscle‑invasive bladder cancer: a systematic review and two‑step meta‑analysis. Oncologist 2016;21(6):708–15. DOI:10.1634/theoncologist.2015‑0440; Vale C.L. Advanced Bladder Cancer (ABC) Meta‑analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and metaanalysis of individual patient data advanced bladder cancer (ABC) meta‑analysis collaboration. Eur Urol 2005;48(2):202–6; discussion 205–6. DOI:10.1016/j.eururo.2005.04.006; Griffiths G., Hall R., Sylvester R. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: long‑term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171–7. DOI:10.1200/JCO.2010.32.3139; Kragelj B., Zaletel‑Kragelj L., Sedmak B. et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005;75(1):44–7. DOI:10.1016/j.radonc.2005.01.007; Tester W., Caplan R., Heaney J. et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119–26. DOI:10.1200/JCO.1996.14.1.119; Lin C.C., Hsu C.H., Cheng J.C. et al. Induction cisplatin and fluorouracil‑based chemotherapy followed by concurrent chemoradiation for muscle‑invasive blad‑der cancer. Int J Radiat Oncol Biol Phys 2009;75(2):442–8. DOI:10.1016/j.ijrobp.2008.11.030; Smith Z.L., Christodouleas J.P., Keefe S.M. et al. Bladder preservation in the treatment of muscle‑invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 2013;112(1):13–25. DOI:10.1111/j.1464‑410X.2012.11762.x; Efstathiou J.A., Spiegel D.Y., Shipley W.U. et al. Long‑term outcomes of selective bladder preservation by combined‑modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61(4):705–11. DOI:10.1016/j.eururo.2011.11.010; Ajib K., Tjong M.C., Tan G.H. et al. Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(12):404–10. DOI:10.5489/cuaj.6459; Royce T.J., Liu Y., Milowsky M.I. et al. Trimodality therapy with or without neoadjuvant chemotherapy for muscle‑invasive bladder cancer. Clin Genitourin Cancer 2021;19(4):362–8. DOI:10.1016/j.clgc.2021.03.007; Mitin T., Dengina N., Chernykh M. et al. Management of muscle invasive bladder cancer with bladder preservation in Russia: a survey‑based analysis of current practice and the impact of an educational workshop on clinical expertise. J Cancer Educ 2021;36(5):1005–13. DOI:10.1007/s13187‑020‑01728‑y; Cowan R.A., McBain C.A., Ryder W.D. et al. Radiotherapy for muscle‑invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose‑escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(1):197–207. DOI:10.1016/j.ijrobp.2003.10.018; Huddart R.A., Hall E., Hussain S.A. et al. Randomized noninferiority trial of reduced high‑dose volume versus standard volume radiation therapy for muscle‑invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013;87(2):261–9. DOI:10.1016/j.ijrobp.2013.06.2044; Nixon R.G., Chang S.S., Lafleur B.J. et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167(2 Pt 1):502–5. DOI:10.1097/00005392‑200202000‑00012; Kefer J.C., Voelzke B.B., Flanigan R.C. et al. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology 2005;66(6):1251–5. DOI:10.1016/j.urology.2005.07.006; Stein J.P., Penson D.F., Wu S.D., Skinner D.G. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the litera‑ture. J Urol 2007;178(3 Pt 1):756–60. DOI:10.1016/j.juro.2007.05.013; Rödel C., Grabenbauer G.G., Kühn R. et al. Combined‑modality treatment and selective organ preservation in invasive bladder cancer: long‑term results. J Clin Oncol 2002;20(14):3061–71. DOI:10.1200/JCO.2002.11.027; Arcangeli G., Arcangeli S., Strigari L. A systematic review and meta‑analysis of clinical trials of bladder‑sparing trimodality treatment for muscle‑invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015;94(1):105–15. DOI:10.1016/j.critrevonc.2014.11.007; Van Leeuwen C.M., Oei A.L., Crezee J. et al. The alfa and beta of tumours: a review of parameters of the linear‑quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13(1):96. DOI:10.1186/s13014‑018‑1040‑z; Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28(33):4912–8. DOI:10.1200/JCO.2010.28.4950; James N.D., Hussain S.A., Hall E. et al. Radiotherapy with or without chemotherapy in muscle‑invasive bladder cancer. N Engl J Med 2012;366(16):1477–88. DOI:10.1056/NEJMoa1106106; Choudhury A., Swindell R., Logue J.P. et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle‑invasive bladder cancer. J Clin Oncol 2011;29(6):733–8. DOI:10.1200/JCO.2010.31.5721; Thompson C., Joseph N., Sanderson B. et al. Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys 2017;97(4):732–9. DOI:10.1016/j.ijrobp.2016.11.040; Hussain S.A., Stocken D.D., Peake D.R. et al. Long‑term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004;90(11):2106–11. DOI:10.1038/sj.bjc.6601852; Choudhury A., Porta N., Hall E. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta‑analysis of the BC2001 and BCON trials. Lancet Oncol 2021;22(2):246–55. DOI:10.1016/S1470‑2045(20)30607‑0; Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58(3):380–5. DOI:10.1016/s0090‑4295(01)01219‑5; Pos F.J., Hart G., Schneider C., Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64(4):1168–73. DOI:10.1016/j.ijrobp.2005.09.023; Whalley D., Caine H., McCloud P. et al. Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. Radiat Oncol 2015;10:205. DOI:10.1186/s13014‑015‑0499‑0; Murthy V., Gupta P., Baruah K. et al. Adaptive radiotherapy for carcinoma of the urinary bladder: long‑term outcomes with dose escalation. Clin Oncol (R Coll Radiol) 2019;31(9):646–52. DOI:10.1016/j.clon.2019.06.005; Hafeez S., Warren‑Oseni K., McNair H.A. et al. Prospective study delivering simultaneous integrated high‑dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle‑invasive bladder cancer. Int J Radiat Oncol Biol Phys 2016;94(5):1022–30. DOI:10.1016/j.ijrobp.2015.12.379; Kibrom A.Z., Knight K.A. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci 2015;62(4):277–85. DOI:10.1002/jmrs.129; Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long‑term results in 1,054 patients. J Clin Oncol 2001;19(3):666–75. DOI:10.1200/JCO.2001.19.3.666; Tunio M.A., Hashmi A., Qayyum A. et al. Whole‑pelvis or bladder‑only chemoradiation for lymph node‑negative invasive bladder cancer: single‑institution experience. Int J Radiat Oncol Biol Phys 2012;82(3):e457–62. DOI:10.1016/j.ijrobp.2011.05.051; Mari A., Kimura S., Foerster B. et al. A systematic review and meta‑analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123(1):11–21. DOI:10.1111/bju.14417; Werntz R.P., Smith Z.L., Packiam V.T. et al. The impact of lymphovascular invasion on risk of upstaging and lymph node metastasis at the time of radical cystectomy. Eur Urol Focus 2020;6(2):292–7. DOI:10.1016/j.euf.2018.09.019; Goldsmith B., Baumann B.C., He J. et al. Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 2014;88(3):603–10. DOI:10.1016/j.ijrobp.2013.11.211; Hall E., Hussain S.A., Porta N. et al. BC2001 long‑term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high‑dose volume RT in muscle‑invasive bladder cancer. J Clin Oncol 2017;35:280. DOI:10.1200/JCO.2017.35.6_suppl.280; Джойнер М.С., ван дер Когель О.Д. Основы клинической радиобиологии. Гл. 18. Совместное применение лучевой и химиотерапии. Пер. с англ. М.: БИНОМ. Лаборатория знаний, 2013. 600 с.; Coen J.J., Zhang P., Saylor P.J. et al. Bladder preservation with twice‑a‑day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle‑invasive bladder cancer: NRG/RTOG 0712 – а randomized phase II trial. J Clin Oncol 2019;37(1):44–51. DOI:10.1200/JCO.18.00537; Гладков О. А., Зуков Р.А., Матвеев В. Б. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(32). DOI:10.18027/2224‑5057‑2021‑11‑3s2‑32; Portner R., Bajaj A., Elumalai T. et al. A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle‑invasive bladder cancer. Clin Transl Radiat Oncol 2021;31:1–7. DOI:10.1016/j.ctro.2021.08.003; Caffo O., Thompson C., De Santis M. et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle‑invasive bladder cancer: a pooled individual data analysis of eight phase I–II trials. Radiother Oncol 2016;121(2):193–8. DOI:10.1016/j.radonc.2016.09.006; Wettstein M.S., Rooprai J.K., Pazhepurackel C. et al. Systematic review and meta‑analysis on trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: does the current quality of evidence justify definitive conclusions? PLoS One 2019;14(4):e0216255. DOI:10.1371/journal.pone.0216255; Mak R.H., Hunt D., Shipley W.U. et al. Long‑term outcomes in patients with muscleinvasive bladder cancer after selective bladder‑preserving combined‑modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI:10.1200/JCO.2014.57.5548; Bladder cancer: diagnosis and management of bladder cancer: ©NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int 2017;120(6):755–65. DOI:10.1111/bju.14045; Payne H., Adamson A., Bahl A. et al. Chemicaland radiation‑induced haemorrhagic cystitis: current treatments and challenges. BJU Int 2013;112(7):885– 97. DOI:10.1111/bju.12291; Kool R., Marcq G., El‑Achkar A. et al. Refining assessment of response to radiation‑based therapy for muscleinvasive bladder cancer: is post‑treatment tumor bed biopsy always necessary? Urol Oncol 2021;39(5):299.e7–14. DOI:10.1016/j.urolonc.2020.10.001; Spencer K., Jones C.M., Girdler R. et al. The impact of the COVID‑19 pandemic on radiotherapy services in England UK: a population‑based study. Lancet Oncol 2021;22(3):309–20. DOI:10.1016/S1470‑2045(20)30743‑9; Mitin T., Choudhury A. The role of biomarkers in bladder preservation management of muscle‑invasive bladder cancer. World J Urol 2019;37(9):1767–72. DOI:10.1007/s00345‑018‑2480‑7; Wu C.T., Chen W.C., Chang Y.H. et al. The role of PD‑L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 2016;6:19740. DOI:10.1038/srep19740; https://oncourology.abvpress.ru/oncur/article/view/1534

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1534
https://doi.org/10.17650/1726-9776-2022-18-2-142-163

Bladder leiomyosarcoma originating from the muscular elements of the bladder mucosa (clinical case) ; Лейомиосаркома мочевого пузыря, исходящая из мышечных элементов слизистой оболочки мочевого пузыря (клинический случай)

Συγγραφείς: I. A. Reva, K. M. Nyushko, E. N. Plekhanova, V. D. Sanikovich, A. S. Chernushenko, N. D. Akhvlediani, D. Yu. Pushkar, И. А. Рева, К. М. Нюшко, Е. Н. Плеханова, В. Д. Саникович, А. С. Чернушенко, Н. Д. Ахвледиани, Д. Ю. Пушкарь

Πηγή: Cancer Urology; Том 18, № 1 (2022); 106-111 ; Онкоурология; Том 18, № 1 (2022); 106-111 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: активное наблюдение, bladder, organ-preserving treatment, transurethral resection, active surveillance, мочевой пузырь, органосохраняющее лечение, трансуретральная резекция

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1512/1355; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1068; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1069; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1070; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1071; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1072; Labanaris A.P., Zugor V., Meyer B. et al. Urinary bladder leiomyosarcoma in adults. Int Urol Nephrol 2008;40(2):311–6. DOI:10.1007/s11255-007-9288-5.; Menon A.R., Puthalath R.T., Suresh N., Hegde S. Organ preservation in leiomyosarcoma bladder: case report and review of literature. Urol Ann 2018;10(2):233–6. DOI:10.4103/UA.UA_109_17.; Baurys W., Landes R.R. Leiomyosarcoma of the bladder; report of a case. Guthrie Clin Bull 1946;15:127–32.; Zieschang H., Koch R., Wirth M.P., Froehner M. Leiomyosarcoma of the urinary bladder in adult patients: a systematic review of the literature and meta-analysis. Urol Int 2019;102(1):96–101. DOI:10.1159/000494357.; Coiner B.L., Cates J., Kamanda S. et al. Leiomyosarcoma of the urinary bladder: a SEER database study and comparison to leiomyosarcomas of the uterus and extremities/trunk. Ann Diagn Pathol 2021;53:151743. DOI:10.1016/j.anndiagpath.2021.151743.; Rodríguez D., Preston M.A., Barrisford G.W. et al. Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol 2014;32(7):958–65. DOI:10.1016/j.urolonc.2014.01.025.; Parekh D.J., Jung C., O’Conner J. et al. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblas­toma and review of bladder sarcomas. Urology 2002;60(1):164. DOI:10.1016/s0090-4295(02)01701-6.; Brucker B., Ernst L., Meadows A., Zderic S. A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006;46(7):811–4. DOI:10.1002/pbc.20506.; Ramírez Sevilla C., Admella-Salvador C., Romero-Martin J.A. et al. Bladder leiomyosarcoma 25 years after treatment with cyclophosphamide in patient with history of retinoblastoma. Urol Int 2018;100(1): 119–21. DOI:10.1159/000437442.; Tanguay C., Harvey I., Houde M. et al. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003;16(5):512–4. DOI:10.1097/01.MP.0000068237.38715.D9.; Онкологическая база данных My Cancer Genome. Доступно по: https://www.mycancergenome.org/content/disease/leiomyosarcoma/.; Rosser C.J., Slaton J.W., Izawa J.I. et al. Clinical presentation and outcome of highgrade urinary bladder leiomyosarcoma in adults. Urology 2003;61(6):1151–5. DOI:10.1016/s0090-4295(03)00021-9.; Hamadalla N.Y., Rifat U.N., Safi K.C. et al. Leiomyosarcoma of the urinary bladder: a review and a report of two further cases. Arab J Urol 2013;11(2):159–64. DOI:10.1016/j.aju.2013.03.004.; Slaoui H., Sanchez-Salas R., Validire P. et al. Urinary bladder leiomyosarcoma: primary surgical treatment. Urol Case Rep 2014;2(4):137–8. DOI:10.1016/j.eucr.2014.05.002.; https://oncourology.abvpress.ru/oncur/article/view/1512

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1512
https://doi.org/10.17650/1726-9776-2022-18-1-106-111

Практические рекомендации по лекарственному лечению рака мочевого пузыря

Συγγραφείς: О. А. Гладков, Р. А. Зуков, В. Б. Матвеев, Т. Митин, Д. А. Носов, А. М. Попов

Πηγή: Malignant tumours; Том 12, № 3s2-1 (2022); 589-606 ; Злокачественные опухоли; Том 12, № 3s2-1 (2022); 589-606 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: внутрипузырная терапия, трансуретральная резекция

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1051/747; https://www.malignanttumors.org/jour/article/view/1051

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1051
https://doi.org/10.18027/2224-5057-2022-12-3s2-589-606

Efficacy and safety of bovhyaluronidase azoximer in patients undergoing transurethral resection of the prostate ; Эффективность и безопасность бовгиалуронидазы азоксимера у пациентов после трансуретральной резекции предстательной железы

Συγγραφείς: T. V. Shatylko, R. I. Safiullin, S. I. Gamidov, A. Yu. Popova, S. H. Izhbaev, A. F. Mazitova, Т. В. Шатылко, Р. И. Сафиуллин, С. И. Гамидов, А. Ю. Попова, С. Х. Ижбаев, А. Ф. Мазитова

Πηγή: Andrology and Genital Surgery; Том 23, № 2 (2022); 47-53 ; Андрология и генитальная хирургия; Том 23, № 2 (2022); 47-53 ; 2412-8902 ; 2070-9781

Θεματικοί όροι: фиброз, benign prostatic hyperplasia, bladder neck stenosis, bladder outlet obstruction, fibrosis, transurethral resection, urethral stricture, доброкачественная гиперплазия предстательной железы, инфравезикальная обструкция, стеноз шейки мочевого пузыря, стриктура уретры, трансуретральная резекция

Περιγραφή αρχείου: application/pdf

Relation: https://agx.abvpress.ru/jour/article/view/564/462; Rodriguez-Nievez J.A., Macoska J.A. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 2013;10(9):546–50. DOI:10.1038/nrurol.2013.149.; Пушкарь Д.Ю., Раснер П.И., Абоян И.А. и др. «СНМП/ДГПЖ – кто лечит?». Результаты эпидемиологического исследования. Урология 2019;(1):5–15. DOI:10.18565/urology.2019.16.5-15.; Ahyai S.A., Gilling P., Kaplan S.A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010;58(3):384–97. DOI:10.1016/j.eururo.2010.06.005.; Primiceri G., Castellan P., Marchioni M. et al. Bladder neck contracture after endoscopic surgery for benign prostatic obstruction: incidence, treatment, and outcomes. Curr Urol Rep 2017;18(10):79. DOI:10.1007/s11934-017-0723-6.; Tang Y., Li J., Pu C. et al. Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. J Endourol 2014;28(9):1107–14. DOI:10.1089/end.2014.0188.; Давыдов Д.С., Цариченко Д.Г., Безруков Е.А. и др. Осложнения гольмиевой лазерной энуклеации гиперплазии предстательной железы. Урология 2018;(1):42–7. DOI:10.18565/urology.2018.1.42-47.; Castellani D., Wroclawski M.L., Pirola G.M. et al. Bladder neck stenosis after transurethral prostate surgery: a systematic review and meta-analysis. World J Urol 2021;39(11):4073–83. DOI:10.1007/s00345-021-03718-1.; Панферов А.С., Котов С.В., Юсуфов А.Г. и др. Лапароскопическая трансвезикальная аденомэктомия при крупных и гигантских размерах предстательной железы. Экспериментальная и клиническая урология 2022;15(1):102–10. DOI:10.29188/2222-85432022-15-1-102-110.; Rosenbaum C.M., Vetterlein M.W., Fisch M. et al. Contemporary outcomes after transurethral procedures for bladder neck contracture following endoscopic treatment of benign prostatic hyperplasia. J Clin Med 2021;10(13):2884. DOI:10.3390/jcm10132884.; Garza-Montúfar M.E., Cobos-Aguilar H., Treviño-Baez J.D., Pérez-Cortéz P. Factors associated with urethral and bladder neck stricture after transurethral resection of the prostate. J Endourol 2021;35(9):1400–4. DOI:10.1089/end.2020.0847.; Попков В.М., Шатылко Т.В., Фомкин Р.Н. Прогнозирование результата патогистологического исследования простаты с помощью искусственной нейронной сети. Саратовский научно-медицинский журнал 2014;10(2):328–32.; Шатылко Т.В., Попков В.М., Королёв А.Ю., Фомкин Р.Н. Гемодинамические характеристики кровотока в простатических артериях и доброкачественная гиперплазия простаты. Вестник Кыргызско-Российского славянского университета 2019;19(1):60–4.; Busetto G.M., Giovannone R., Antonini G. et al. Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int 2015;116(1):117–23. DOI:10.1111/bju.12917.; Redshaw J.D., Broghammer J.A., Smith T.G. et al. Intralesional injection of mitomycin C at transurethral incision of bladder neck contracture may offer limited benefit: TURNS Study Group. J Urol 2015;193(2):587–92. DOI:10.1016/j.juro.2014.08.104.; Harmon W.J., Barrett D.M., Qian J. et al. Transurethral enzymatic ablation of the prostate: canine model. Urology 1996;48(2):229–33. DOI:10.1016/S0090-4295(96)00082-9.; Мартов А.Г., Ергаков Д.В. Использование препарата Лонгидаза® при повторных трансуретральных операциях на нижних мочевых путях. Эффективная фармакотерапия 2017;(4):18–25.; Шатохин М.Н., Мальцев В.Н., Конопля А.И., Теодорович О.В. Клинико-иммунологическая эффективность различных лекарственных форм Лонгидазы у больных с доброкачественной гиперплазией предстательной железы в сочетании с хроническим простатитом. Системный анализ и управление в биомедицинских системах 2010;9(2):327–31.; Зайцев А.В., Пушкарь Д.Ю., Ходырева Л.А., Дударева А.А. Хронический бактериальный простатит, расстройства мочеиспускания у мужчин и фиброз предстательной железы. Урология 2016;(4):114–21. PMID: 28247738.; https://agx.abvpress.ru/jour/article/view/564

Διαθεσιμότητα: https://agx.abvpress.ru/jour/article/view/564
https://doi.org/10.17650/2070-9781-2022-23-2-47-53